ICLR vs. INSM: ICON vs. Insmed Stock Comparison

Company Profile

ICON (ICLR) and Insmed (INSM) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but ICLR is classified in Life Sciences Tools & Services while INSM is classified in Biotechnology.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Insmed (INSM) reports a negative ROE of -72.45%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile ICON (ICLR) reports 4.70%, ranking against industry peers normally.

Insmed (INSM) reports a negative net margin of -39.85%, usually indicating a net loss over the period. Meanwhile ICON (ICLR) reports 5.26%, ranking against industry peers normally.

Insmed (INSM) reports a negative operating margin of -15.60%, usually indicating that operating costs exceeded revenue at the operating-income line. Meanwhile ICON (ICLR) reports 10.73%, ranking against industry peers normally.

Profitability Metrics

Growth

Insmed (INSM) at 66.73% sits in the top revenue growth quartile, while ICON (ICLR) at 0.76% is closer to the peer norm — faster top-line expansion for INSM.

Only one side can be read here: ICON (ICLR) reports EPS growth of -71.56%, ranked against its industry; Insmed (INSM) has no EPS growth figure this period.

Growth Metrics

Financial Strength

Insmed (INSM) at 2.86 keeps current ratio within its industry’s typical mid-range, while ICON (ICLR) at 1.32 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for ICLR.

ICON (ICLR) at 0.38 carries an industry-typical debt-to-equity mix, while Insmed (INSM) at 1.01 uses more debt funding than most peers.

Financial Strength Metrics

Dividends

Neither ICON (ICLR) nor Insmed (INSM) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Neither ICON (ICLR) nor Insmed (INSM) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Dividend Metrics

Valuation

An earnings multiple is available for just one side: ICON (ICLR) trades at 81.90 times trailing earnings, ranked against its peers, while Insmed (INSM) has no P/E ratio this period.

ICON (ICLR) at 1.86 sits in the cheaper P/S ratio quartile while Insmed (INSM) at 16.52 prices around its industry’s middle — ICLR costs less per dollar of sales, though read it alongside growth and margins.

ICON (ICLR) at 1.68 sits in the lower P/B ratio quartile relative to book while Insmed (INSM) at 34.55 prices above its industry range — a wide valuation gap against assets.

Valuation Metrics